List of works - Pierantonio Menna

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

scientific article published in June 2009

An introduction to the metabolic determinants of anthracycline cardiotoxicity.

scientific article published on January 2007

Anthracycline cardiotoxicity

scientific article published on 02 June 2011

Anthracycline cardiotoxicity

scientific article published on 01 January 2008

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

scientific article published on January 2010

Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite

scientific article published on 01 December 2000

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

scientific article (publication date: June 2004)

Cardiotoxicity of antitumor drugs

scientific article published on 01 April 2008

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

scientific article published on 22 April 2011

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

scientific article published on 19 January 2006

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies

scientific article published on 29 November 2006

Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.

scientific article published on January 2004

Doxorubicin degradation in cardiomyocytes

scientific article published on 27 April 2007

Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy ⬇️

scientific article published on December 1, 2001

Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia

scientific article published on 01 August 2019

Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue

scientific article

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

scientific article published on December 2014

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind

scientific article

Matters of the Heart: The Case of TNF -Targeting Drugs

scientific article published on 01 April 2011

Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.

scientific article published on 21 November 2003

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies

scientific article published on 13 April 2006

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin

scientific article published on 15 February 2012

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin

scientific article published on 15 February 2012

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis

scientific article published on 12 September 2012

Pharmacological foundations of cardio-oncology.

scientific article

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship

scientific article published on 16 June 2014

The concomitant management of cancer therapy and cardiac therapy

scientific article

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

scientific article published on 28 November 2012

List of works by Pierantonio Menna

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

An introduction to the metabolic determinants of anthracycline cardiotoxicity.

Anthracycline cardiotoxicity

Anthracycline cardiotoxicity

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

Cardiotoxicity of antitumor drugs

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies

Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.

Doxorubicin degradation in cardiomyocytes

Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy ⬇️

Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia

Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind

Matters of the Heart: The Case of TNF -Targeting Drugs

Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis

Pharmacological foundations of cardio-oncology.

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship

The concomitant management of cancer therapy and cardiac therapy

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.